Antinuclear antibodies (ANA) screening
19.00 BGN
General information:
The test provides information about the presence of autoantibodies in the patient. ANA screening is a widely used serological marker aiding in the diagnosis of systemic autoimmune diseases. Anti-nuclear antibodies are a group of antibodies directed against DNA, various proteins and protein complexes of the cell nucleus. Patients who show a positive result should be examined to determine the specificity of the autoantibodies found in the serum (ANA-profile). A significant number of autoimmune diseases are associated with the presence of autoantibodies directed against these nuclear antigens. Such are systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma, autoimmune hepatitis, vasculitis, endocarditis, Sjogren's syndrome, Sharp's syndrome, CREST syndrome, polymyositis, etc. In addition to rheumatoid diseases and collagenoses, ANA screening can be positive in drug-induced lupus and autoimmune reproductive failure syndrome (CAPH). The latter is associated with repeated abortions, unexplained sterility or endometriosis. Antinuclear antibodies (ANA) can cross the placenta and pose a risk for fetal harm and complications during pregnancy.
ANA screening includes the following autoantibodies:
- Histones
- dsDNA
- Rib-P
- nRNP/Sm
- Sm
- SS-A/Ro
- SS-B
- Scl-70,
- Jo-1
- Centromeres
- AMA-M2 заедно с HEp-2 cell nuclear extract
Sample reqired:
Venous blood
Key words:
ANA screening